Molecular target
BCR-ABL Tyrosine Kinase
Constitutively-active oncogenic fusion kinase produced by the Philadelphia chromosome (t(9;22)) in chronic myeloid leukemia. Selective inhibition by imatinib (Gleevec — first targeted therapy approved 2001) transformed CML from rapidly fatal to a manageable chronic disease. Subsequent kinase inhibitors (dasatinib, nilotinib) target the same lesion.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on BCR-ABL Tyrosine Kinase
These medications have BCR-ABL Tyrosine Kinase among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.